International Stem Cell Corporation (OTCQB: ISCO) builds
shareholder value through its research with stem cells, otherwise known as
cells that can both proliferate (divide) and change (differentiate) into more
specialized cells, such as skin, nerve or liver cells. The most powerful stem
cells are known as ‘pluripotent’, as they have the promise of becoming
virtually any cell in the human body. The first pluripotent stem cells to be
studied were embryonic stem cells (ESC) taken from donated human embryos. ISCO’s
new class of pluripotent human stem cells are derived from unfertilized eggs.
These stem cells, known as human parthenogenetic stem cells (hPSC) avoid the
ethical issues associated with ESC while retaining many of the advantages.
The company’s work does not begin and end with research.
International Stem Cell Corporation’s primary goal is to transform its research
into treatment for those suffering with moderate to severe Parkinson’s disease,
and if recent developments are any indication of the company’s progress in this
area, the recent announcement that enrollment has started for its upcoming
phase I clinical trial should remove all doubt. The trial is scheduled to take
place at the Royal Melbourne Hospital in Australia.
In a news release, Dr. Russell Kern, executive vice
president and chief scientific officer of ISCO, recently noted, “Enrollment in
this trial is an important milestone… Promising preclinical results support our
expectation that ISC-hpNSC will bring a long-needed solution for patients
suffering from Parkinson’s disease.”
ISCO is a publicly traded biotechnology company which
developed a powerful new stem cell technology called parthenogenesis that could
significantly advance the field of regenerative medicine by addressing the
problem of immune-rejection. Parthenogenesis (from the Greek parthenos, meaning
“virgin” and genesis, meaning “birth”) uses unfertilized human eggs to create
hpSC that can be immune-matched to millions of people. A relatively small
number of hpSC lines could provide sufficient immune-matched cells to cover a
large percentage of the world’s population.
The company’s human cell culture products also comprise
adult stem cells and reagents for regenerative medicine; human prostate cells
and specialized media to study prostate disease; human renal and bladder cells
and media to study renal and bladder diseases; human corneal cells and media
for the study of corneal disease; and other cell culture reagents and
supplements for the growth, staining, and freezing of human cells.
International Stem Cell Corporation was founded in 2001 and is headquartered in
Carlsbad, California.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
